S&P 500   2,671.01 (+0.28%)
DOW   22,759.48 (+0.35%)
QQQ   197.42 (+0.48%)
AAPL   262.09 (-0.14%)
FB   169.10 (+2.14%)
MSFT   165.34 (+0.04%)
GOOGL   1,193.25 (+0.85%)
AMZN   2,016.26 (+0.93%)
CGC   14.49 (+1.05%)
NVDA   260.45 (-2.96%)
MU   46.61 (+0.52%)
GE   7.04 (-2.76%)
TSLA   545.87 (+5.74%)
AMD   47.94 (+0.88%)
T   30.32 (+2.99%)
ACB   0.80 (+0.00%)
F   4.67 (+3.09%)
NFLX   374.34 (-1.48%)
BAC   22.25 (+4.02%)
GILD   74.91 (-3.63%)
DIS   101.34 (+1.77%)
S&P 500   2,671.01 (+0.28%)
DOW   22,759.48 (+0.35%)
QQQ   197.42 (+0.48%)
AAPL   262.09 (-0.14%)
FB   169.10 (+2.14%)
MSFT   165.34 (+0.04%)
GOOGL   1,193.25 (+0.85%)
AMZN   2,016.26 (+0.93%)
CGC   14.49 (+1.05%)
NVDA   260.45 (-2.96%)
MU   46.61 (+0.52%)
GE   7.04 (-2.76%)
TSLA   545.87 (+5.74%)
AMD   47.94 (+0.88%)
T   30.32 (+2.99%)
ACB   0.80 (+0.00%)
F   4.67 (+3.09%)
NFLX   374.34 (-1.48%)
BAC   22.25 (+4.02%)
GILD   74.91 (-3.63%)
DIS   101.34 (+1.77%)
S&P 500   2,671.01 (+0.28%)
DOW   22,759.48 (+0.35%)
QQQ   197.42 (+0.48%)
AAPL   262.09 (-0.14%)
FB   169.10 (+2.14%)
MSFT   165.34 (+0.04%)
GOOGL   1,193.25 (+0.85%)
AMZN   2,016.26 (+0.93%)
CGC   14.49 (+1.05%)
NVDA   260.45 (-2.96%)
MU   46.61 (+0.52%)
GE   7.04 (-2.76%)
TSLA   545.87 (+5.74%)
AMD   47.94 (+0.88%)
T   30.32 (+2.99%)
ACB   0.80 (+0.00%)
F   4.67 (+3.09%)
NFLX   374.34 (-1.48%)
BAC   22.25 (+4.02%)
GILD   74.91 (-3.63%)
DIS   101.34 (+1.77%)
S&P 500   2,671.01 (+0.28%)
DOW   22,759.48 (+0.35%)
QQQ   197.42 (+0.48%)
AAPL   262.09 (-0.14%)
FB   169.10 (+2.14%)
MSFT   165.34 (+0.04%)
GOOGL   1,193.25 (+0.85%)
AMZN   2,016.26 (+0.93%)
CGC   14.49 (+1.05%)
NVDA   260.45 (-2.96%)
MU   46.61 (+0.52%)
GE   7.04 (-2.76%)
TSLA   545.87 (+5.74%)
AMD   47.94 (+0.88%)
T   30.32 (+2.99%)
ACB   0.80 (+0.00%)
F   4.67 (+3.09%)
NFLX   374.34 (-1.48%)
BAC   22.25 (+4.02%)
GILD   74.91 (-3.63%)
DIS   101.34 (+1.77%)
Log in

NASDAQ:PSNLPersonalis Stock Price, Forecast & News

$7.92
-0.34 (-4.12 %)
(As of 04/7/2020 03:19 PM ET)
Add
Compare
Today's Range
$7.87
Now: $7.92
$8.29
50-Day Range
$4.75
MA: $7.79
$10.48
52-Week Range
$4.27
Now: $7.92
$31.88
Volume4,323 shs
Average Volume527,745 shs
Market Capitalization$249.24 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies. It offers NeXT Platform, which provides data for cancer therapy development, personalized therapies, therapy selection, and diagnostics. The company also provides a complementary liquid biopsy assay that analyzes various human genes versus. It serves approximately 45 biopharmaceutical customers, including a range of pharmaceutical companies. The company was founded in 2011 and is headquartered in Menlo Park, California.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.40 out of 5 stars


Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PSNL
CUSIPN/A
CIKN/A
Phone650-752-1300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$65.21 million
Book Value$3.42 per share

Profitability

Miscellaneous

Employees147
Market Cap$249.24 million
Next Earnings Date6/24/2020 (Estimated)
OptionableNot Optionable

Receive PSNL News and Ratings via Email

Sign-up to receive the latest news and ratings for PSNL and its competitors with MarketBeat's FREE daily newsletter.


Personalis (NASDAQ:PSNL) Frequently Asked Questions

How has Personalis' stock been impacted by COVID-19 (Coronavirus)?

Personalis' stock was trading at $6.02 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, PSNL shares have increased by 31.6% and is now trading at $7.92. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Personalis?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Personalis in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Personalis.

When is Personalis' next earnings date?

Personalis is scheduled to release its next quarterly earnings announcement on Wednesday, June 24th 2020. View our earnings forecast for Personalis.

How were Personalis' earnings last quarter?

Personalis (NASDAQ:PSNL) announced its earnings results on Wednesday, March, 25th. The company reported ($0.21) earnings per share for the quarter, topping analysts' consensus estimates of ($0.25) by $0.04. The firm earned $18.15 million during the quarter, compared to analyst estimates of $17.75 million. View Personalis' earnings history.

What price target have analysts set for PSNL?

5 brokerages have issued twelve-month target prices for Personalis' shares. Their forecasts range from $13.00 to $29.00. On average, they anticipate Personalis' stock price to reach $22.50 in the next twelve months. This suggests a possible upside of 184.1% from the stock's current price. View analysts' price targets for Personalis.

Has Personalis been receiving favorable news coverage?

News headlines about PSNL stock have trended very negative recently, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Personalis earned a news impact score of -3.3 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news aboutPersonalis.

Who are some of Personalis' key competitors?

What other stocks do shareholders of Personalis own?

Who are Personalis' key executives?

Personalis' management team includes the following people:
  • Mr. John West, Co-Founder, CEO, Pres & Director (Age 62)
  • Prof. Russ B. Altman M.D., Ph.D., Co-Founder and Member of Clinical & Scientific Advisory Board
  • Mr. Euan A. Ashley, Co-Founder and Member of Clinical & Scientific Advisory Board
  • Dr. Atul Butte, Co-Founder and Member of Clinical & Scientific Advisory Board
  • Dr. Michael Snyder Ph.D., Co-Founder and Member of Clinical & Scientific Advisory Board

When did Personalis IPO?

(PSNL) raised $100 million in an IPO on Thursday, June 20th 2019. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen and Company served as the underwriters for the IPO and Oppenheimer was co-manager.

What is Personalis' stock symbol?

Personalis trades on the NASDAQ under the ticker symbol "PSNL."

How do I buy shares of Personalis?

Shares of PSNL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Personalis' stock price today?

One share of PSNL stock can currently be purchased for approximately $7.92.

How big of a company is Personalis?

Personalis has a market capitalization of $249.24 million and generates $65.21 million in revenue each year. The company earns $-25,080,000.00 in net income (profit) each year or ($1.39) on an earnings per share basis. Personalis employs 147 workers across the globe. View additional information about Personalis.

What is Personalis' official website?

The official website for Personalis is http://www.personalis.com/.

How can I contact Personalis?

Personalis' mailing address is 1330 O`BRIEN DRIVE, MENLO PARK CA, 94025. The company can be reached via phone at 650-752-1300 or via email at [email protected]

This page was last updated on 4/7/2020 by MarketBeat.com Staff

Featured Article: Circuit Breakers

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel